EICHORCondition: Renal Impairment · Sponsor: Taiho Oncology, Inc.
This is a Phase I, open-label study evaluating the PK of S-1 components and their metabolites in patients with advanced solid tumors and varying degrees of renal function. Patients will be stratified by baseline 24-hour creatinine clearance(CrCL) into 4 cohorts using the normal clearance formula: Group A: Control Group B:Mild renal dysfunction Group C:Moderate renal function and Group D: Severe renal dysfunction. Six patients will be enrolled into each cohort.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Premiere Oncology of Arizona | Scottsdale, Arizona, United States | — |
| LAC/USC Medical Center | Los Angeles, California, United States | — |
| Premiere Oncology | Santa Monica, California, United States | — |
| Yale Cancer Center | New Haven, Connecticut, United States | — |
| University of Kentucky/Division of Hematology/Oncology and Blood Marrow Transplantation | Lexington, Kentucky, United States | — |
| University of Maryland/Greenebaum Cancer Center | Baltimore, Maryland, United States | — |
| Washington University School of Medicine | St Louis, Missouri, United States | — |
| Cancer Research & Treatment Center/University of New Mexico | Albuquerque, New Mexico, United States | — |
| The Institute for Drug Development | San Antonio, Texas, United States | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT00398307